Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

3-Methylglutaconic aciduria--lessons from 50 genes and 977 patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Functional Assessment of Variants Associated with Wolfram Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of SLC26A4 mutations, morphology, and hearing in pendred syndrome and NSEVA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. The Natural History of Hearing Loss in Pendred Syndrome and Non-Syndromic Enlarged Vestibular Aqueduct

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Saskia B Wortmann
  • Leo A J Kluijtmans
  • Richard J Rodenburg
  • Jörn Oliver Sass
  • Jessica Nouws
  • Edwin P van Kaauwen
  • Tjitske Kleefstra
  • Lisbeth Tranebjaerg
  • Maaike C de Vries
  • Pirjo Isohanni
  • Katharina Walter
  • Fowzan S Alkuraya
  • Izelle Smuts
  • Carolus J Reinecke
  • Francois H van der Westhuizen
  • David Thorburn
  • Jan A M Smeitink
  • Eva Morava
  • Ron A Wevers
Vis graf over relationer
Elevated urinary excretion of 3-methylglutaconic acid is considered rare in patients suspected of a metabolic disorder. In 3-methylglutaconyl-CoA hydratase deficiency (mutations in AUH), it derives from leucine degradation. In all other disorders with 3-methylglutaconic aciduria the origin is unknown, yet mitochondrial dysfunction is thought to be the common denominator. We investigate the biochemical, clinical and genetic data of 388 patients referred to our centre under suspicion of a metabolic disorder showing 3-methylglutaconic aciduria in routine metabolic screening. Furthermore, we investigate 591 patients with 50 different, genetically proven, mitochondrial disorders for the presence of 3-methylglutaconic aciduria. Three percent of all urine samples of the patients referred showed 3-methylglutaconic aciduria, often in correlation with disorders not reported earlier in association with 3-methylglutaconic aciduria (e.g. organic acidurias, urea cycle disorders, haematological and neuromuscular disorders). In the patient cohort with genetically proven mitochondrial disorders 11% presented 3-methylglutaconic aciduria. It was more frequently seen in ATPase related disorders, with mitochondrial DNA depletion or deletion, but not in patients with single respiratory chain complex deficiencies. Besides, it was a consistent feature of patients with mutations in TAZ, SERAC1, OPA3, DNAJC19 and TMEM70 accounting for mitochondrial membrane related pathology. 3-methylglutaconic aciduria is found quite frequently in patients suspected of a metabolic disorder, and mitochondrial dysfunction is indeed a common denominator. It is only a discriminative feature of patients with mutations in AUH, TAZ, SERAC1, OPA3, DNAJC19 TMEM70. These conditions should therefore be referred to as inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature.
TidsskriftJournal of Inherited Metabolic Disease
Udgave nummer6
Sider (fra-til)913-21
Antal sider9
StatusUdgivet - nov. 2013

ID: 42503444